glp-1 and gip/glp-1 receptor agonists Potential Use of for Respiratory Disorders: Where Are We at? Targeting GLP-1, GIP & GCG
Description
High fill rates of GLP-1 receptor agonist prescriptions in those with mood disorders could indicate that multimorbidity begets more treatment.
World Health Organization
As new uses emerge, companies must carefully monitor patient health and integrate behavior change strategies
Heres what evidence says about absorption and claims, plus safety checks and questions to ask your clinician.
The results of the PIONEER-3 trial have now been published in the renowned journal Journal of the American Medical Association (JAMA) and are said to be trend-setting for future therapy of type 2 diabetes.
